MNMD Jan 2026 12.000 call
- Business Wire
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
NEW YORK, June 20, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD.
- Simply Wall St.
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) 18% loss last week hit both individual investors who own 46% as well as institutions
Key Insights Significant control over Mind Medicine (MindMed) by retail investors implies that the general public has...
- Business Wire
MindMed to Participate in June Conferences
NEW YORK, May 28, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences:
